| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JCONREL.2003.08.006 |
| P698 | PubMed publication ID | 14644577 |
| P2093 | author name string | Paul R Lockman | |
| David D Allen | |||
| Russell J Mumper | |||
| Moses O Oyewumi | |||
| Karen E Roder | |||
| Joanna M Koziara | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | 271-282 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Journal of Controlled Release | Q6295046 |
| P1476 | title | Brain uptake of thiamine-coated nanoparticles | |
| P478 | volume | 93 |
| Q36962295 | Absence of Cytotoxicity towards Microglia of Iron Oxide (α-Fe2O3) Nanorhombohedra. |
| Q38095485 | Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles |
| Q36903797 | Antibiological barrier nanovector technology for cancer applications. |
| Q90289038 | Application of Paclitaxel-loaded EGFR Peptide-conjugated Magnetic Polymeric Liposomes for Liver Cancer Therapy |
| Q35829128 | Application of drug delivery technologies in lead candidate selection and optimization |
| Q38896543 | Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis. |
| Q46889161 | Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles |
| Q26861389 | Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines |
| Q26744462 | Biomaterials for the Treatment of Alzheimer's Disease |
| Q25932820 | Biosafety, occupational health and nanotechnology |
| Q50930074 | Biosynthesis and safety evaluation of ZnO nanoparticles. |
| Q28385334 | Biotests and Biosensors for Ecotoxicology of Metal Oxide Nanoparticles: A Minireview |
| Q39018455 | Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers |
| Q39520806 | Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers |
| Q48872882 | Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? |
| Q29615481 | Cancer nanotechnology: opportunities and challenges |
| Q28084729 | Central nervous system toxicity of metallic nanoparticles |
| Q37416147 | Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases |
| Q37715006 | Chapter 10 - Solid lipid nanoparticles and microemulsions for drug delivery The CNS. |
| Q37714988 | Chapter 3 - Colloidal systems for CNS drug delivery |
| Q42000200 | Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles |
| Q38755622 | Dendrimer-mediated approaches for the treatment of brain tumor. |
| Q34797004 | Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies |
| Q37856301 | Drug delivery to the CNS and polymeric nanoparticulate carriers |
| Q47260839 | Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery |
| Q23919409 | Evaluation of nano- and submicron particle penetration through ten nonwoven fabrics using a wind-driven approach |
| Q37833981 | Fate and transport of engineered nanomaterials in the environment |
| Q57809514 | Hesperidin alleviates zinc oxide nanoparticle induced hepatotoxicity and oxidative stress |
| Q48627318 | Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain |
| Q28395653 | In vitro genotoxic effects of ZnO nanomaterials in human peripheral lymphocytes |
| Q37798178 | In vivo methods to study uptake of nanoparticles into the brain. |
| Q36247082 | Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models. |
| Q33911056 | Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic |
| Q43098424 | Liver and brain imaging through dimercaptosuccinic acid-coated iron oxide nanoparticles |
| Q37428097 | Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease |
| Q64064209 | Nanomaterials for Drug Delivery to the Central Nervous System |
| Q38522125 | Nanoneurotherapeutics approach intended for direct nose to brain delivery. |
| Q38136249 | Nanoneurotoxicity to nanoneuroprotection using biological and computational approaches |
| Q37800505 | Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System |
| Q27006099 | Novel delivery strategies for glioblastoma |
| Q42914677 | Physicochemical characterization andin vivobioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug |
| Q37076360 | Polymeric nanoparticles for the drug delivery to the central nervous system |
| Q48257348 | Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer's disease model |
| Q57169956 | Recent Status of Nanomaterial Fabrication and Their Potential Applications in Neurological Disease Management |
| Q26775886 | Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson's disease models |
| Q38269392 | Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood-Brain Barrier |
| Q46825326 | Solid lipid nanoparticles as delivery systems for bromocriptine |
| Q39976449 | Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line |
| Q37639557 | Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. |
| Q36731366 | SyM-BBB: a microfluidic Blood Brain Barrier model |
| Q39275254 | Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates. |
| Q34818171 | TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs |
| Q37705215 | Targeted immunomodulation using antigen-conjugated nanoparticles |
| Q37354233 | Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders |
| Q37368323 | Targeting anti-HIV drugs to the CNS. |
| Q30406070 | Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study |
| Q38791773 | Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation |
| Q40063227 | The cellular and genomic response of an immortalized microglia cell line (BV2) to concentrated ambient particulate matter |
| Q28386644 | The effect of ventilation, age, and asthmatic condition on ultrafine particle deposition in children |
| Q35972521 | Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging |
| Q44696669 | Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications |
Search more.